NextGenCapCG
5 년 전
Agreed there. I was looking around and see that a hedge fund called Sabby Management took a control position back around January. Not the biggest fund ever, but the principal of the fund just bought a $10mm palace in Miami so they are doing alright.
Obviously it could be part of a short strategy or something else, but anytime I see sophisticated money playing in OTC land, that interests me. Based on what I have read, it seems like Rosetta still owns the IP. They sold all their other assets. Assuming that money went to pay off balance sheet liabilities, it seems like this company could reinvigorate itself by licensing their patents and/or beginning operations again with (to your point) the help of some debt or equity capital from Wall Street. Especially because it seems that their tech has real utility.
I have a starter position already. Going to try to accumulate more shares at a reasonable price.
makinezmoney
6 년 전
$ROSGQ: NEWS..... $IDXG buys out Assets and Employees
Interpace Diagnostics (IDXG) Buys Select Assets of Rosetta Genomics Out of Bankruptcy
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated bioinformatics and commercial company that provides clinically useful molecular diagnostic tests, related first line assessments and pathology services for improved patient diagnosis and management, today announced that it has successfully acquired a majority of the equipment of Rosetta Genomics’ Philadelphia laboratory through a bankruptcy auction. Interpace acquired, for an undisclosed amount of cash, 64 select lots of laboratory assets, including freezers, refrigerators, PCR machines, advanced slide scanning equipment as well as laboratory supplies and specialty furniture. The laboratory assets will further support the Company’s CLIA and CAP certified lab expansion in its Pittsburgh, PA and New Haven, CT laboratories.
Since the bankruptcy filing of Rosetta Genomics in May 2018, the Company has also hired several former key Rosetta employees and select former Rosetta customers have transitioned their accounts to Interpace’s thyroid assays. Interpace believes it is uniquely licensed to process thyroid slide biopsies, the primary specimen type for Rosetta’s Reveal™ product.
According to Jack Stover, President and CEO of Interpace, “We are proud to be serving many of the former Rosetta customers and are very pleased to have several highly-qualified Rosetta employees join the Interpace team. The cost effective, specialty equipment we acquired will be especially helpful as we continue to expand our new product offerings, including our slide products even further, under our combined ThyGeNEXT™ / ThyraMIR® assays for indeterminate thyroid nodules.”
makinezmoney
6 년 전
$ROSGF: Yes I know that.... Banking on Genoptix Buyout
Or even another offer that presents itself to bail them out.
They still hold IP.
Someone will come for that.
Thanks for the LINK !
****************************************************
( ROSG ROSGF ) Rosetta Announces That Completion of Genoptix Transaction UncertainFont size: A | A | A
5:51 PM ET 5/29/18 | Dow Jones
RELATED QUOTES
10:55 AM ET 6/4/18
Symbol Last % Chg
ROSGF
0.04 -48.53%
Real time quote.
Rosetta Contemplates Bankruptcy Filing May 31, 2018
PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / May 29, 2018 / Rosetta Genomics Ltd. (NASDAQ: ROSG; OTC PINK: ROSGF)(the "Company") announced today that the pending of merger of a subsidiary of Genoptix, Inc. with the Company has not occurred as scheduled and that Genoptix has refused to provide assurances that it intends to complete the transaction. Unless the transaction is completed by May 30, 2018, the Company intends to file for bankruptcy protection in Israel and the United States.
Genoptix has asserted the existence of a "Material Adverse Effect" affecting the Company and breaches of representations and warranties, which the Company disputes. The absence of a Material Adverse Effect since February 27, 2018, the date of the merger agreement, and continued accuracy of the Company's representations and warranties except as would not have a Material Adverse Effect are conditions to Genoptix's obligations to complete the transaction.
SOURCE: Rosetta Genomics Ltd
> Dow Jones Newswires
May 29, 2018 17:51 ET (21:51 GMT)